HRMY (Harmony Biosciences Holdings) Tariff Resilience Score: 7/10 (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HRMY Harmony Biosciences Holdings Inc HRMY
94 GF Score
Price $38.74
GF Value $46.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Harmony Biosciences Holdings Tariff Resilience Score?

Harmony Biosciences Holdings HRMY +1.35% 94 Tariff Resilience Score is 7 as of Aug. 06, 2026. GuruFocus rates HRMY with a GF Score™ of 94/100 and a GF Value™ of $46.81 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,367 Biotechnology companies, Harmony Biosciences Holdings ranks better than 90.34% on this metric.

Harmony Biosciences Holdings has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Harmony Biosciences Holdings has Harmony Biosciences has limited exposure to tariffs due to its focus on pharmaceuticals, which often enjoy exemptions. Its supply chain is somewhat global, but the impact of tariffs on its operations has been minimal. The company has strong pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Harmony Biosciences Holdings might have Highly Resilient.

Harmony Biosciences Holdings  (NAS:HRMY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Harmony Biosciences Holdings Tariff Resilience Score Related Terms

HRMY vs SION, URGN, PVLA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Harmony Biosciences Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harmony Biosciences Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Tariff Resilience Score falls into.


HRMY
94GF Score
Harmony Biosciences Holdings Inc HRMY
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Harmony Biosciences Holdings (HRMY) has a Tariff Resilience Score of 7 as of Aug. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Harmony Biosciences Holdings ranks #132 out of 1367 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Harmony Biosciences Holdings' Tariff Resilience Score too high?
Harmony Biosciences Holdings' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Harmony Biosciences Holdings' value of 7 is 75% above this industry median. Based on the distribution chart, Harmony Biosciences Holdings ranks #132 out of 1367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Harmony Biosciences Holdings has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Tariff Resilience Score compare to SION and URGN?
According to the Biotechnology industry distribution chart, Harmony Biosciences Holdings ranks #132 out of 1367 companies for Tariff Resilience Score. This places Harmony Biosciences Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Harmony Biosciences Holdings' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harmony Biosciences Holdings's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harmony Biosciences Holdings's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.81, compared to a current price of $38.74 — trading 17.2% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Harmony Biosciences Holdings' overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Tariff Resilience Score is 7 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?

Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued. The current stock price of $38.74 is trading 17.2% below its estimated GF Value™ of $46.81. GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.

Key valuation signals for HRMY:

  • Tariff Resilience Score: 7
  • GF Value™: $46.81 vs. price of $38.74 (17.2% below fair value)
  • GF Score™: 94/100 with 2 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1367)

No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harmony Biosciences Holdings Business Description

Address 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score

Get the complete analysis for HRMY

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.74
Price
$46.81
GF Value